Advanced HCC: Which First-line Treatment Is Best?

TOPLINE:

In a meta-analysis assessing first-line treatment options for advanced hepatocellular carcinoma (HCC), atezolizumab plus bevacizumab demonstrated the highest overall probability of delaying deterioration across key quality-of-life (QoL) domains and outperformed other treatment options when integrating health-related QoL with overall survival benefits.

METHODOLOGY:

The therapeutic landscape for advanced HCC has "evolved dramatically since 2018," the authors explained. Current first-line options include combinations of immune checkpoint inhibitors (ICIs), such as atezolizumab plus bevacizumab and durvalumab plus tremelimumab , as well as other combinations and monotherapy. However, there's limited evidence comparing these options in terms of survival benefit and QoL.

R